Product launches to fuel lupus market growth

28 February 2014

The systemic lupus erythematosus (SLE) treatment market in the seven major countries (7MM) will increase significantly in value over the coming years, jumping from around $473.6 million in 2012 to $1.1 billion by 2022, at a compound annual growth rate (CAGR) of 9.36%.

According to a recent report by research and consulting firm GlobalData, the total revenues for lupus nephritis (LN) in the 7MM – the USA, France, Germany, Italy, Spain, the UK and Japan – will climb from an estimated $216.6 million in 2012 to $505.9 million by the end of the forecast period, representing a slightly lower CAGR of 8.86%.

GlobalData attributes the anticipated growth in both markets to the higher uptake of GlaxoSmithKline’s Benlysta (belimumab) and off-label Rituxan (rituximab), from Roche and Biogen Idec, along with the introduction of new biological therapies and overall increase in prevalent cases of SLE and LN across the 7MM during the forecast period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK